Author:
Lenzi Monika,Winder Thomas
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. de Ruiter EJ, Mulder FJ, Koomen BM, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34(6):1125–32. https://doi.org/10.1038/s41379-020-0644-7.
2. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733.
3. Kato K, Sun J, Shah MA, et al. Pembrolizumab plus chemotherapy vs chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase III KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215. https://doi.org/10.1016/j.annonc.2020.08.2298.
4. Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the checkmate 648 study. J Clin Oncol. 2021;39(18):LBA4001–LBA4001.
5. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203. https://doi.org/10.1056/NEJMoa2032125.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Innovative strategies in gastrointestinal cancer;memo - Magazine of European Medical Oncology;2022-02